Effect of Sodium Tanshinon IIA and Simvastatin on Serum Levels of Inflammatory Markers in Patients with Coronary Heart Disease:A Radomized Controlled Trial

Effect of Sodium Tanshinon IIA and Simvastatin on Serum Levels of Inflammatory Markers in Patients with Coronary Heart Disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002361

Enrollment

Unknown

Registered

2012-07-22

Start date

2012-08-01

Completion date

Unknown

Last updated

2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Interventions

Intervention group:Sodium Tanshinon IIA+STS-statin

Control:STS-statin

Eligibility

Sex/Gender

All

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Between 35 and 75 years of age; 2. Either have a previous history of myocardial infarction or have at least one coronary artery stenosis >=50% confirmed by coronary angiography; 3. Subjects must currently be hospitalized with either unstable angina or an acute non-ST segment elevation myocardial infarction; 4. Participants must have the diagnosis of Blood stasis syndrome; 5. Serum high-sensitivity C reactive protein level between 3 mg/L and 15 mg/L; 6. Participants must either currently be taking statin medications or have a serum LDL-C >= 80 mg/dL.

Exclusion criteria

Exclusion criteria: 1. Infection, fever, trauma, burn injury, or surgery within one month prior to recruitment; 2. Subjects have previously undergone or currently be planning to undergo surgical intervention for CHD; 3. Patients with a reduced platelet count or a tendency to bleed or hemorrhage; 4. Study participants currently be taking antibiotics or using TCM preparations that relieve fever or clear internal heat; 5. Patients with severe heart failure indicated by an ejection fraction < 35% ; 6. Patients were diagnosed with cancer; 7. Patients with tuberculosis, or rheumatoid arthritis or other autoimmune diseases; 8. Patients have a history of serious pulmonary, hepatic, renal, neurological, psychiatric, or hematological diseases; 9. Patients who may become noncompliant or may participate in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Serum high-sensitivity C reactive protein level;	—

Secondary

Measure	Time frame
The levels of other inflammatory mediators, including IL-6, TNF??, VCAM-1, CD40 and soluble CD40 ligand (sCD40L), MCP-1, andMMP-9;The extent of improvement in angina;Safety;	—

Countries

China

Contacts

Public ContactHao Xu

xuhaotcm@hotmail.com+86 13241755581

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 22, 2026